Eric Dobmeier

Eric Dobmeier is a seasoned biotechnology executive currently serving as a Venture Partner at Samsara BioCapital and holding multiple leadership roles at various biotechnology companies. Dobmeier is the Chairman of the Board at Jade Biosciences and IntegerBio, overseeing advancements in therapies for autoimmune and serious viral diseases, respectively. As the Lead Independent Director at Bluejay Therapeutics, Dobmeier contributes to the development of treatments for viral and liver diseases. Additionally, Dobmeier holds directorships at Janux Therapeutics, Abdera Therapeutics, and Structure Therapeutics, focusing on cancer therapies and innovative drug developments. prior experience includes serving as Director and Advisor at ProfoundBio, and a significant tenure as President & CEO of Chinook Therapeutics, where Dobmeier led the company in creating therapies for chronic kidney disease. Academic credentials include a J.D. from the University of California, Berkeley - School of Law, and an A.B. in History from Princeton University.